Related Experiment Video
Updated: Oct 7, 2025
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
42.4K
Monoclonal Antibodies Generation: Updates and Protocols on Hybridoma Technology
Ahmed Muhsin1,2, Roberto Rangel3, Long Vien1
1Department of Immunology, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX, USA.
Methods in Molecular Biology (Clifton, N.J.)
|January 7, 2022
Summary
Hybridoma technology, a cornerstone since 1975, continues to be a preferred method for generating antigen-specific antibodies. Recent advancements and core facility expertise have produced over 350 antibodies for diverse applications.
Area of Science:
- Biotechnology
- Immunology
- Molecular Biology
Background:
- Hybridoma technology, established in 1975, has significantly impacted scientific and medical discoveries.
- Numerous advancements, including phage and yeast display libraries, single B-cell cloning, and in silico methods, have been developed to generate novel antibodies.
- Despite new techniques, hybridoma technology remains prevalent for antibody production due to its ability to preserve natural immune cell functions and cross species barriers.
Purpose of the Study:
- To describe recent methods for antibody generation utilized by the Monoclonal Antibodies Core Facility at the University of Texas-M.D. Anderson Cancer Center.
- To highlight the continued relevance and adaptability of hybridoma technology in antibody production.
- To showcase the facility's success in generating a substantial number of antibodies for various applications.
Main Methods:
- Utilizing established hybridoma technology, which involves fusing antibody-producing B cells with myeloma cells.
- Implementing recent advancements and techniques refined over the last decade within a core facility setting.
- Leveraging expertise to generate antibodies from immunized animals of different species, including humans, and employing in silico approaches.
Main Results:
- The Monoclonal Antibodies Core Facility has generated over 350 antibodies in the past 10 years.
- The described methods have facilitated the production of antibodies for a wide range of applications.
- Hybridoma technology continues to be a reproducible and effective method, even in resource-limited laboratory settings.
Conclusions:
- Hybridoma technology remains a vital and versatile tool in antibody production, complementing newer methodologies.
- The Monoclonal Antibodies Core Facility has demonstrated significant success in generating high-quality antibodies through refined techniques.
- The preservation of natural antibody functions and the ability to cross species barriers underscore the enduring value of hybridoma technology.
